159 related articles for article (PubMed ID: 1683350)
41. Molecular analysis of multidrug resistance in feline lymphoma cells.
Okai Y; Nakamura N; Matsushiro H; Kato H; Setoguchi A; Yazawa M; Okuda M; Watari T; Hasegawa A; Tsujimoto H
Am J Vet Res; 2000 Sep; 61(9):1122-7. PubMed ID: 10976746
[TBL] [Abstract][Full Text] [Related]
42. A CRE/ATF-like site in the upstream regulatory sequence of the human interleukin 1 beta gene is necessary for induction in U937 and THP-1 monocytic cell lines.
Gray JG; Chandra G; Clay WC; Stinnett SW; Haneline SA; Lorenz JJ; Patel IR; Wisely GB; Furdon PJ; Taylor JD
Mol Cell Biol; 1993 Nov; 13(11):6678-89. PubMed ID: 8413264
[TBL] [Abstract][Full Text] [Related]
43. CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells.
Chen KG; Sale S; Tan T; Ermoian RP; Sikic BI
Mol Pharmacol; 2004 Apr; 65(4):906-16. PubMed ID: 15044620
[TBL] [Abstract][Full Text] [Related]
44. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells.
Daschner PJ; Ciolino HP; Plouzek CA; Yeh GC
Breast Cancer Res Treat; 1999 Feb; 53(3):229-40. PubMed ID: 10369069
[TBL] [Abstract][Full Text] [Related]
45. Characterization of promoter elements involved in the down-regulation of topoisomerase IIalpha expression in a drug-resistant cell line.
Saxena D; Yiu GK; Ni X; Huang KC; Mantovani R; Jacquemin-Sablon AG; Ng SW
Gene; 2004 Nov; 342(1):145-55. PubMed ID: 15527974
[TBL] [Abstract][Full Text] [Related]
46. Identification of regulatory regions within the KAI1 promoter: a role for binding of AP1, AP2 and p53.
Marreiros A; Czolij R; Yardley G; Crossley M; Jackson P
Gene; 2003 Jan; 302(1-2):155-64. PubMed ID: 12527206
[TBL] [Abstract][Full Text] [Related]
47. Identification of sterol-independent regulatory elements in the human ATP-binding cassette transporter A1 promoter: role of Sp1/3, E-box binding factors, and an oncostatin M-responsive element.
Langmann T; Porsch-Ozcürümez M; Heimerl S; Probst M; Moehle C; Taher M; Borsukova H; Kielar D; Kaminski WE; Dittrich-Wengenroth E; Schmitz G
J Biol Chem; 2002 Apr; 277(17):14443-50. PubMed ID: 11839742
[TBL] [Abstract][Full Text] [Related]
48. Antitumor effects of cytosine deaminase and thymidine kinase fusion suicide gene under the control of mdr1 promoter in mdr1 positive leukemia cells.
Wang X; Ji C; Ma D; Zhao J; Hou M; Yu H; Zang S
Leuk Lymphoma; 2007 Aug; 48(8):1600-9. PubMed ID: 17701592
[TBL] [Abstract][Full Text] [Related]
49. 5-Azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs.
Efferth T; Futscher BW; Osieka R
Blood Cells Mol Dis; 2001; 27(3):637-48. PubMed ID: 11482878
[TBL] [Abstract][Full Text] [Related]
50. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells.
Hui RC; Francis RE; Guest SK; Costa JR; Gomes AR; Myatt SS; Brosens JJ; Lam EW
Mol Cancer Ther; 2008 Mar; 7(3):670-8. PubMed ID: 18347152
[TBL] [Abstract][Full Text] [Related]
51. Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene.
Heils A; Teufel A; Petri S; Seemann M; Bengel D; Balling U; Riederer P; Lesch KP
J Neural Transm Gen Sect; 1995; 102(3):247-54. PubMed ID: 8788073
[TBL] [Abstract][Full Text] [Related]
52. [Reversion Mechanism Study of PESV to Multidrug Resistance at Leukemia Stem Cell Level].
Yang XD; Shi ZX; Yan LX; Liu BS; Chen HY; Yan TG; Zhang WF; Yang X; Qin HR; Liu C; Ji HX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Jul; 36(7):867-874. PubMed ID: 30634217
[TBL] [Abstract][Full Text] [Related]
53. Sensitization and apoptosis augmentation of K562/ADM cells by anti-multidrug resistance gene peptide nucleic acid and antisense oligodeoxyribonucleotide.
Wei HL; Wu YJ; Jing T; Bai DC; Ma LF
Acta Pharmacol Sin; 2003 Aug; 24(8):805-11. PubMed ID: 12904281
[TBL] [Abstract][Full Text] [Related]
54. DNA-protein interactions in the proximal zeta-globin promoter: identification of novel CCACCC- and CCAAT-binding proteins.
Sabath DE; Koehler KM; Yang WQ; Phan V; Wilson J
Blood Cells Mol Dis; 1998 Jun; 24(2):183-98. PubMed ID: 9642099
[TBL] [Abstract][Full Text] [Related]
55. Protein-DNA interactions in the epsilon-globin gene silencer.
Peters B; Merezhinskaya N; Diffley JF; Noguchi CT
J Biol Chem; 1993 Feb; 268(5):3430-7. PubMed ID: 8429019
[TBL] [Abstract][Full Text] [Related]
56. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.
Huo H; Magro PG; Pietsch EC; Patel BB; Scotto KW
Cancer Res; 2010 Nov; 70(21):8726-35. PubMed ID: 20861184
[TBL] [Abstract][Full Text] [Related]
57. Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1).
Vilaboa NE; Galán A; Troyano A; de Blas E; Aller P
J Biol Chem; 2000 Aug; 275(32):24970-6. PubMed ID: 10816597
[TBL] [Abstract][Full Text] [Related]
58. Heat-shock responsive elements in the induction of the multidrug resistance gene (MDR1).
Kioka N; Yamano Y; Komano T; Ueda K
FEBS Lett; 1992 Apr; 301(1):37-40. PubMed ID: 1360409
[TBL] [Abstract][Full Text] [Related]
59. Reversal of multidrug resistance by tyrosine-kinase inhibitors in a non-P-glycoprotein-mediated multidrug-resistant cell line.
Takeda Y; Nishio K; Niitani H; Saijo N
Int J Cancer; 1994 Apr; 57(2):229-39. PubMed ID: 7908894
[TBL] [Abstract][Full Text] [Related]
60. Transcriptional control of the multi-drug transporter ABCB1 by transcription factor Sp3 in different human tissues.
Gromnicova R; Romero I; Male D
PLoS One; 2012; 7(10):e48189. PubMed ID: 23133566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
